Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890729 · ClinicalTrials.gov registry record · Phase 1
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
A Phase 1 study of Pulmonary Sarcoidosis, sponsored by Xentria.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 20
- Study locations
NCT05890729: Recruiting Phase 1 study of Pulmonary Sarcoidosis, sponsored by Xentria.
NCT05890729 is a Phase 1 study of Pulmonary Sarcoidosis that is actively recruiting participants, run by Xentria. The registered enrollment target is 94 participants, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05890729, a Phase 1 study of Pulmonary Sarcoidosis, is actively recruiting participants, sponsored by Xentria.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 20
- Study locations
Study Summary
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Primary Outcome
Safety and Tolerability
Conditions Studied
Interventions
- DRUG XTMAB-16 or Placebo
Study Locations (20)
Other
- Xentria Investigative Site - Prague
- Xentria Investigative Site - Aalborg
- Xentria Investigative Site - Aarhus
Illinois
- Xentria Investigative Site - Chicago
- Xentria Investigative Site - Chicago
New York
- Xentria Investigative Site - Albany
- Xentria Investigative Site - New York
Alabama
- Xentria Investigative Site - Birmingham
Colorado
- Xentria Investigative Site - Denver
Florida
- Xentria Investigative Site - Jacksonville
Iowa
- Xentria Investigative Site - Iowa City
Maryland
- Xentria Investigative Site - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
What NCT05890729 shows while recruiting
NCT05890729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which XTMAB-16 or Placebo is the first listed.
NCT05890729 names 20 study sites across 16 states, led by Other, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05890729 about?
NCT05890729 is a clinical study titled "A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis". A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
What is the current status of trial NCT05890729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2023-11-10. Estimated completion is 2026-04.
What conditions does trial NCT05890729 study?
This clinical trial studies the following conditions: Pulmonary Sarcoidosis.
What interventions are being tested in trial NCT05890729?
The interventions under investigation include: XTMAB-16 or Placebo (DRUG).
Who is sponsoring clinical trial NCT05890729?
This trial is sponsored by Xentria, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05890729 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RECRUITING · Phase 2
-
Role of Genetic Factors in the Development of Lung Disease
RECRUITING
-
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
ACTIVE NOT RECRUITING · Phase 3
-
The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
COMPLETED · NA
-
Treatment of Pulmonary Sarcoidosis With Pentoxifylline
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI